770 reports of this reaction
2.6% of all EZETIMIBE AND SIMVASTATIN reports
#3 most reported adverse reaction
FATIGUE is the #3 most commonly reported adverse reaction for EZETIMIBE AND SIMVASTATIN, manufactured by Organon LLC. There are 770 FDA adverse event reports linking EZETIMIBE AND SIMVASTATIN to FATIGUE. This represents approximately 2.6% of all 29,702 adverse event reports for this drug.
Patients taking EZETIMIBE AND SIMVASTATIN who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for EZETIMIBE AND SIMVASTATIN, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for EZETIMIBE AND SIMVASTATIN:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 770 FDA reports for EZETIMIBE AND SIMVASTATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.6% of all adverse event reports for EZETIMIBE AND SIMVASTATIN, making it one of the most commonly reported side effect.
If you experience fatigue while taking EZETIMIBE AND SIMVASTATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.